Dara Azar
Stock Analyst at Stifel Nicolaus
(3.40)
# 2,362
Out of 4,993 analysts
18
Total ratings
81.8%
Success rate
17.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dara Azar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INBX Inhibrx Biosciences | Reiterated: Buy | $325 | $112.04 | +190.07% | 7 | Aug 21, 2026 | |
| ELVN Enliven Therapeutics | Reiterated: Buy | $82 | $48.87 | +67.79% | 4 | Aug 13, 2026 | |
| SMMT Summit Therapeutics | Reiterated: Buy | $38 | $16.90 | +124.85% | 7 | Jul 28, 2026 |
Inhibrx Biosciences
Aug 21, 2026
Reiterated: Buy
Price Target: $325
Current: $112.04
Upside: +190.07%
Enliven Therapeutics
Aug 13, 2026
Reiterated: Buy
Price Target: $82
Current: $48.87
Upside: +67.79%
Summit Therapeutics
Jul 28, 2026
Reiterated: Buy
Price Target: $38
Current: $16.90
Upside: +124.85%